European Companies Search Engine
EU funding (€2,197,145): Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision Hor 1 Jun 2020 EU Research and Innovation programme "Horizon"
Overview
Text
Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision
Novel cancer treatments should ideally combine efficacy with selectivity. Tissue toxicity and side-effects are still the norm, however. Although new targeted therapies act with greater precision, the notion of tumour-specific cell death is justly regarded with scepticism. The Swedish company Hamlet Pharma provides new cancer treatments based on a peptide-based molecular approach for targeting and killing tumour cells with greater precision. Its proprietary drug complex, HAMLET (‘Human Alpha-lactalbumin Made LEthal to Tumour cells’) is derived from the human breast milk protein, alpha-lactalbumin, and represents a ground-breaking therapeutic solution with high tumour-killing capacity, high target specificity, killing >40 different types of tumour cells and no demonstrated toxicity. As such, it has the potential to revolutionize cancer treatment. Hamlet Pharma is now advancing HAMLET and the synthetic drug candidate Alpha1H along the clinical development pipeline as anti-cancer therapeutic for early stage bladder cancer. The company is focusing on bladder cancer given the high clinical need for more effective and safe treatment options. Bladder cancer has the highest recurrence rates (70%) and treatment costs per patient among all cancer types (total costs in Europe: >€4.9 billion). Recent successful outcomes include initial Phase I/II clinical trial data, proving that Alpha1H acts with high efficacy without any detectable toxicity. With the EIC Accelerator funding, Hamlet Pharma will finalise Phase I/II clinical safety and efficacy studies and advance development of Alpha1H towards a Phase III trial (i.e. ready for licensing deal or IPO). Conversations with potential licensing partners and investors are ongoing. Alpha1H will be an important showcase of the impact HAMLET will have on cancer treatment (expected cumulative revenues: €350M five years after market approval). Generated revenues will be reinvested into development of HAMLET for other cancer indications.
Funded Companies:
| Company name | Funding amount |
| Hamlet Pharma AB | €2,197,145 |
| Linnane Pharma AB | €0.00 |
Source: https://cordis.europa.eu/project/id/954360
The filing refers to a past date, and does not necessarily reflect the current state.
